Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexarotene oral

Drug Profile

Bexarotene oral

Alternative Names: LGD 1069; LGD 1069 oral; Targretin; Targretin capsules; Targretin oral; Targretyn oral; Targretyn™; Targrexin oral

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Eisai Co Ltd; Minophagen
  • Class Antineoplastics; Benzoic acids; Naphthalenes; Retinoids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists; Protein synthesis inhibitors; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma
  • Discontinued Non-small cell lung cancer; Thyroid cancer

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 22 Jun 2017 Bexarotene licensed to Ewopharma for commercialisation in Hungary and Poland
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top